The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Safety and management of combining immunotherapy and targeted therapy with TACE in uHCC
Stephen Lam Chan, MD, FRCP, Chinese University of Hong Kong, Hong Kong, China, comments the safety outcomes of combining immunotherapy and targeted therapy with transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (uHCC). Cross-trial comparisons indicate the toxicity profile in the EMERALD-1 study (NCT03778957) is similar to individual treatments, even with TACE. This regimen provides a safe and additional treatment option, particularly for patients with high disease burden seeking aggressive treatment. Clinicians should consider specific toxicities and patient preferences when managing this combination therapy. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – AstraZeneca; Eisai; Ipsen; Roche
Consulting or Advisory Role – AstraZeneca; BMS; Eisai; MSD Oncology; Roche
Research Funding – Eisai; Ipsen
